Morphic to Present at the Jefferies 2019 London Healthcare Conference WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...

Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...

Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results - Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its...